A Systemically Administered Unconjugated Antisense Oligonucleotide Targeting DUX4 Improves Muscular Injury and Motor Function in FSHD Model Mice

被引:2
|
作者
Kakimoto, Tetsuhiro [1 ]
Ogasawara, Akira [1 ]
Ishikawa, Kiyoshi [1 ]
Kurita, Takashi [1 ]
Yoshida, Kumiko [1 ]
Harada, Shuichi [1 ]
Nonaka, Taeko [1 ]
Inoue, Yoshimi [1 ]
Uchida, Keiko [1 ]
Tateoka, Takashi [1 ]
Ohta, Tetsuya [1 ]
Kumagai, Shinji [1 ]
Sasaki, Takashi [1 ]
Aihara, Hajime [1 ]
机构
[1] Mitsubishi Tanabe Pharm Corp, Sohyaku Innovat Res Div, 2-26-1 Muraoka Higashi, Fujisawa, Kanagawa 2518555, Japan
关键词
facioscapulohumeral muscular dystrophy; antisense oligonucleotide; muscle injury; motor function; muscle force; DUX4; EXPRESSION;
D O I
10.3390/biomedicines11092339
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Facioscapulohumeral muscular dystrophy (FSHD), one of the most common muscular dystrophies, is caused by an abnormal expression of the DUX4 gene in skeletal muscles, resulting in muscle weakness. In this study, we investigated MT-DUX4-ASO, a novel gapmer antisense oligonucleotide (ASO). MT-DUX4-ASO decreased the expression of DUX4 and its target genes in FSHD patient-derived myoblasts. For the first time, we demonstrated that a systemically administered ASO, even without a ligand for drug delivery, could significantly improve muscle injury and motor function in the ACTA1-MCM/FLExDUX4 (DUX4-TG) mouse model of FSHD. Tamoxifen (TMX) injection transiently induces skeletal-muscle-specific DUX4 expression in DUX4-TG mice, while the skeletal muscles of TMX-untreated DUX4-TG mice have leaky DUX4 expression in a small subset of myofibers similar to those of FSHD patients. Subcutaneous 10 mg/kg of MT-DUX4-ASO at two-week intervals significantly suppressed muscular DUX4 target gene expression, histological muscle injury, and blood muscle injury marker elevation in TMX-untreated DUX4-TG mice. Notably, MT-DUX4-ASO at 10 mg/kg every other week significantly prevented the TMX-induced declines in treadmill test running speed and muscle force in DUX4-TG mice. Thus, the systemically administered unconjugated MT-DUX4-ASO suppressed disease progression in DUX4-TG mice, extending the potential of unconjugated ASOs as a promising FSHD treatment strategy.
引用
收藏
页数:20
相关论文
共 18 条
  • [1] A novel antisense oligonucleotide targeting DUX4 strongly prevents motor function decline in an FSHD model ACTA1-MCM/FLExDUX4 mice.
    Kakimoto, T.
    Ogasawara, A.
    Ishikawa, K.
    Kurita, T.
    Yoshida, K.
    Harada, S.
    Inoue, Y.
    Kumagai, S.
    Sasaki, T.
    Aihara, H.
    NEUROMUSCULAR DISORDERS, 2022, 32
  • [2] Antisense strategies targeting DUX4 and DUX4c as therapeutic approaches for facioscapulohumeral muscular dystrophy (FSHD)
    Vanderplanck, C.
    Tassin, A.
    Ansseau, E.
    Lancelot, C.
    Derenne, A.
    Conotte, S.
    Dudome, V.
    Leroy, B.
    Wilton, S.
    Laoudj-Chenivesse, D.
    Wattiez, R.
    Legrand, A.
    Belayew, A.
    Coppee, F.
    NEUROMUSCULAR DISORDERS, 2015, 25 : S311 - S312
  • [3] Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD)
    Ansseau, Eugenie
    Vanderplanck, Celine
    Wauters, Armelle
    Harper, Scott Q.
    Coppee, Frederique
    Belayew, Alexandra
    GENES, 2017, 8 (03)
  • [4] Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model
    Ngoc Lu-Nguyen
    Malerba, Alberto
    Herath, Shan
    Dickson, George
    Popplewell, Linda
    HUMAN MOLECULAR GENETICS, 2021, 30 (15) : 1398 - 1412
  • [5] Systemic delivery of antisense oligonucleotides targeting DUX4; a promising therapeutic strategy for facioscapulohumeral muscular dystrophy
    Bouwman, L.
    den Hamer, B.
    van den Heuvel, A.
    Franken, M.
    Jackson, M.
    Dwyer, C.
    Tapscott, S.
    Rigo, F.
    van der Maarel, S.
    de Greef, J.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S99 - S99
  • [6] Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy
    Bouwman, Linde F.
    den Hamer, Bianca
    van den Heuvel, Anita
    Franken, Marnix
    Jackson, Michaela
    Dwyer, Chrissa A.
    Tapscott, Stephen J.
    Rigo, Frank
    van der Maarel, Silvere M.
    de Greef, Jessica C.
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2021, 26 : 813 - 827
  • [7] The FORCE(TM) platform achieves robust and durable DUX4 suppression and improves muscle function in facioscapulohumeral muscular dystrophy mouse model
    Picariello, T.
    Natoli, T.
    Yoder, N.
    Yao, M.
    Valdivia, B.
    Tahaei, E.
    Johnson, J.
    Qiu, Q.
    More, P.
    Schlaefke, L.
    Yang, S.
    Basiri, B.
    Weeden, T.
    Beskrovnaya, O.
    Zanotti, S.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [8] Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression
    Lu-Nguyen, Ngoc
    Dickson, George
    Malerba, Alberto
    Popplewell, Linda
    BIOMEDICINES, 2022, 10 (07)
  • [9] AAV.U7-snRNA Targeting DUX4 Prevents Muscle Damage in a Facioscapulohumeral Muscular Dystrophy Mouse Model
    Rashnonejad, Afrooz
    Chermahini, Gholamhossein Amini
    Taylor, Noah M.
    Wein, Nicolas
    Harper, Scott Q.
    MOLECULAR THERAPY, 2021, 29 (04) : 292 - 292
  • [10] Molecular targeting with iNOS antisense oligodeoxynucleotides improves motor function after experimental spinal cord injury.
    Pearse, DD
    Chatzipanteli, K
    Marcillo, AE
    Bunge, MB
    Dietrich, WD
    JOURNAL OF NEUROTRAUMA, 2003, 20 (10) : 1101 - 1101